If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Alimta ® (pemetrexed for injection)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Alimta Summary of Product Characteristics (SmPC)
Alimta (pemetrexed): Density, pH and other physical and chemical properties
Relevant physical and chemical characteristics of Alimta are provided, including osmolality, density, pH, and sensitivity to oxygen, moisture or light.
is a powder for concentrate for solution for infusion.1
is a white to either light yellow or green-yellow lyophilised
precautions to be taken before handling or administering Alimta and
for instructions on reconstitution and dilution of Alimta before
administration, see summary of product characteristics section 6.6.1
relevant characteristics of Alimta is provided in Table
osmolality of Alimta 500 mg solution reconstituted with 20 mL
0.9 % sodium chloride at 25°C is 514 mOsm/kg of
density of Alimta is approximately 1.02 g/mL at 25°C if
Alimta is reconstituted with 0.9 % Sodium Chloride aqueous
solution as directed
pH of Alimta is between 6.6 & 7.8 when reconstituted in 0.9 %
Sodium Chloride Injection
(pemetrexed disodium) degrades by oxidation. Alimta is oxygen
sensitive and exposure to air will affect the stability. The
manufacturing process was developed to minimize oxidative
degradation by reducing exposure of pemetrexed solution to oxygen
and upon completion of lyophilization cycle the vacuum is
neutralized with sterile filtered nitrogen thus controlling the
oxygen level in the drug product vial headspace.
does not impact the stability of intact vials of Alimta.
(The lyophilized powder in the intact vials of Alimta contains
is not sensitive to light exposure.
Alimta [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review:May 20, 2021
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com